Kids and dementia patients enjoy 'smiles and love'
Children from St James the Great and residents of the Greenhive care home in Peckham meet in a library where they share classic stories, and use immersive lights and audio narration to connect with each other.
The founder of the scheme, John Ramsay, said it was intended to "destigmatise the world of dementia" and was a form of care that was not about physical or medical needs.
"It's about making them happy, about their feelings, about the engagement, smiles, love."
He added: "It's about working out what you can do when you're living with a cognitive impairment and how you can engage with the world around you, including with different generations".
He said the programme, called Social Ability, gave children the skills to interact with older people with cognitive impairment, a condition that could affect their grandparents or parents.
Mr Ramsay said: "Often we're too ready to lock a door so that someone can't get out, and that only increases the isolation which is already there if you are living with a cognitive impairment".
A care home resident, Brenda, said the meetings improve her emotional wellbeing.
"I think it's fantastic for them, it's got them all happy and active. I'm enjoying it. It's nice to see the smiles on their faces.
"I'm good with children and I enjoy seeing them."
Mercy Mautsi, a care home manager, said it was "refreshing" because "most young children don't know what a care home looks like and they've got this fear of people with dementia.
"Without this project, Brenda and the children, they would only have that stereotypical idea of a care home which is where people old people are just sitting, here can understand and make conversations and friends."
One of the pupils, Angel, said she felt "really connected" with Brenda.
"I saw like a really fun side of her when she was playing with us.
"I hope this brings Brenda happiness and I hope she can come to the library every day or maybe like once a week or something."
Listen to the best of BBC Radio London on Sounds and follow BBC London on Facebook, X and Instagram. Send your story ideas to hello.bbclondon@bbc.co.uk
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Government pledges to ‘transform care' for people with ME
The Government has pledged to give hundreds of thousands of people living with chronic fatigue syndrome 'improved care closer to home' as it acknowledged that many patients with the condition 'struggle' to get appropriate care. The Department of Health and Social Care said it is 'committed to changing attitudes and transforming care' for people with Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS) as it prepared to publish a new plan to improve care for people with the condition. It comes after the high-profile death of a young woman from the disease. Maeve Boothby-O'Neill, 27, suffered with ME for a decade before she died at home in Exeter in October 2021 from severe malnutrition. Her inquest heard how she had been admitted to the Royal Devon and Exeter Hospital three times that year for treatment for malnutrition. The 10-day hearing focused on the final few months of her life, by which time she was confined to bed, unable to chew food and had difficulty drinking because she was not able to sit up. Miss Boothby-O'Neill, the daughter of Sean O'Neill, a journalist with The Times newspaper, had been suffering from fatigue since the age of 13, which got worse after she completed her A-levels. Deborah Archer, now an area coroner for Devon, Plymouth and Torbay, concluded Miss Boothby-O'Neill had died from natural causes 'because of severe myalgic encephalomyelitis (ME)'. Last year she wrote to the Government to highlight a lack of specialist beds, 'extremely limited' training for doctors and lack of available funding for research and treatment of the condition. On Tuesday, the Government said that it has created a plan which 'outlines clear steps to improve care for patients, by investing in research and offering access to care in the community'. The Department of Health and Social Care (DHSC) acknowledged that many people with the condition 'currently struggle to access appropriate care tailored to their complex condition'. The plan, which is expected to be published on Tuesday, will include new training for NHS workers, DHSC said. And the document will also include funding for research, the DHSC said. Public health minister Ashley Dalton, said: 'ME/CFS is a debilitating illness that can severely limit patients' ability to participate in everyday activities, maintain employment, or enjoy family and social life. 'Today's plan will help tackle the stigma and lack of awareness of this condition through improved training for NHS staff. 'And through our neighbourhood health services, we will ensure patients suffering from the effects of ME/CFS can access quality care, closer to home, as pledged in our 10-Year Health Plan. But Action for ME said that the plan 'does not go far enough'. Sonya Chowdhury, chief executive of the charity, said: 'We appreciate the time DHSC has put into the delivery plan and their engagement with us and the ME community throughout. 'However, the plan simply does not go far enough. We are at the stage now where we need more than rhetoric, we need to take a strategic approach if we want a different outcome. What is proposed in the plan will not offer this. 'We must have a funded, dedicated research hub to leverage our world-leading life sciences sector to unlock treatments and ultimately cures for ME. 'Without a commitment to better co-ordinate research, people with ME will continue to be neglected, overlooked and, for many, confined to their homes. 'ME charities have been calling for this funding to be accelerated for years and we are still not seeing a strategic approach to address this historic shortfall. Once again, it feels like people with ME have been ignored.' Dr Charles Shepherd, honorary medical advisor and trustee at the ME Association, said: 'Whilst today's announcement is an important step forward in helping to improve the quality of life of people with ME/CFS, the Government must now go much further to improve their medical care and management and help to fund much needed biomedical research into cause and treatment.'
Yahoo
4 hours ago
- Yahoo
New tool can identify children likely to become obese as adults
A tool which can measure a child's risk of becoming obese in later life has been created by scientists. It is hoped that the new resource will one day mean that those at highest risk will get targeted support to prevent them from becoming obese in the first place. The tool, which assesses a person's genetic risk of obesity, works twice as well as any other obesity risk predictor, academics said. As well as identifying children at risk of obesity, it can also predict how well obese adults will respond to targeted weight loss programmes. Academics used detail on genetic variations from more than five million people to create a tool called a polygenic risk score, which analyses people's genetics to work out their risk of developing obesity. The tool could explain 17.6% of variation in body mass index score (BMI) from people in the UK, they found. Researchers, led by academics at the universities of Copenhagen and Bristol, tested whether the risk score was associated with obesity using datasets of the physical and genetic characteristics of more than 500,000 people. This included checking the tool on people taking part in the 'Children of the 90s' study – a long-term study in Bristol tracking families as children age. They found that it could successfully predict weight gain during childhood – from the age of just two and a half – through to adolescence. 'Overall, these data show that polygenic scores have the potential to improve obesity prediction, particularly when implemented early in life,' the authors wrote in the journal, Nature Medicine. Lead author of the research, assistant professor Roelof Smit from the University of Copenhagen, said: 'What makes the score so powerful is the consistency of associations between the genetic score and body mass index before the age of five and through to adulthood – timing that starts well before other risk factors start to shape their weight later in childhood. 'Intervening at this point could theoretically make a huge impact.' He told the PA news agency that BMI is not a good predictor for a child's obesity risk in later life but the genetic predictor can offer insight into the risk from early years. 'Essentially it's fixed at conception already very early in life, you're able to essentially quantify what someone's innate predisposition is for BMI,' he said. 'So, being able to say something about someone's innate biology for obesity risk.' Meanwhile, the research team also looked at people taking part in 'intensive lifestyle intervention' programmes. People with a higher risk score lost more weight, but were also more likely to regain it. Prof Smit added: 'There is a huge amount of variation in how people respond to these interventions. 'What we observed was the higher someone's score was, the more they tended to respond to the intervention – people who had a higher score tended to lose more weight in the first year. 'And we also saw that people who had the higher scores tended to gain more weight.' Dr Kaitlin Wade, associate professor in epidemiology at the University of Bristol and second author on the paper, said: 'Obesity is a major public health issue, with many factors contributing to its development, including genetics, environment, lifestyle and behaviour. 'These factors likely vary across a person's life, and we believe that some of these originate in childhood. 'We were delighted to contribute data from the Children of the 90s study to this exceptional and insightful research into the genetic architecture of obesity. 'We hope this work will contribute to detecting individuals at high risk of developing obesity at an earlier age, which could have a vast clinical and public health impact in the future.' Solve the daily Crossword
Yahoo
5 hours ago
- Yahoo
Major HRT supplier sanctioned after whistleblowers raise concerns over patient safety
A major UK supplier of menopause drug HRT has been sanctioned after whistleblowers claimed patients were being put at risk, it has emerged. A group of employees from Theramex, which supplies HRT treatments to millions of patients in the UK, wrote a letter to the pharmaceutical regulator Association of the British Pharmaceutical Industry over allegations the company was not following regulatory standards and may 'jeopardise' patient safety. The whistleblowers claimed some products featured inaccurate prescribing information and failed to highlight common side effects. They claimed they had been forced to contact the regulator after their attempts to raise issues internally were brushed off. The company has now admitted it breached regulatory codes, amounting to 'bringing discredit upon, and reducing confidence in the pharmaceutical industry', according to an interim case report from the ABPI. It also failed to maintain high standards and provide accurate and up-to-date prescribing information, the report said. Theramex is a global pharmaceutical company specialising in women's health products, such as hormone replacement therapy (HRT) and fertility treatments. Theramex UK is its London-based arm. It supplies common HRT therapies including Evorel, Bijuve and Intrarosa. From April to June 2025, there were 760,000 prescriptions of Evorel and 2,748 prescriptions of Bijuve, according to data from the NHS Business Services Authority. In 2023-24, there were 2.8 million prescriptions of Evorel. One employee wrote the complaint on behalf of a group, according to the complaint published by the Prescription Medicines Code of Practice Authority, which is part of the ABPI. The complaint, filed in October 2024, said: 'We are a group of employees from various cross-functional teams at Theramex, and we are writing to express our growing concerns regarding the company's adherence to regulatory standards and the accountability of its leadership. 'While we have attempted to escalate these issues internally on numerous occasions, there has been a consistent lack of action or meaningful response, which leaves us with no choice but to seek external guidance and support.' The complaint alleged that some of Theramex's products, such as Intrarosa and Evorel, had not had their prescribing information updated. In the case of Evorel, information for health professionals was 'incomplete' and did not include information on common side effects such as uterine spasms and vaginal infection, the letter claimed. For another drug, the letter alleged that prescribing information had not been updated for five years. The complaint warned: 'This oversight can lead to healthcare professionals (HCPs) not being fully informed of potential risks, which could jeopardise patient safety.' The PMCPA panel found Theramix's 'failure to provide accurate and complete prescribing information was unacceptable'. The employees also alleged the company failed to comply with regulators for clinical trial compliance warning. 'The lack of resources within Theramex's global headquarters to ensure compliance with these standards is alarming,' it said. Finally, the letter alleged the company has a 'blame culture' that was 'deeply concerning.' In response to the complaint, Theramex UK said it took its obligations under the ABPI code of practice 'very seriously' and launched an internal investigation. It said that, although it had a process to update prescribing information, this was not sufficiently robust to ensure prescribing information was immediately updated. The pharma company acknowledged it did not meet standards concerning this allegation and admitted that, at the time of the complaint, it did not have a process in place for clinical studies. The employees' letter claimed it had tried to escalate matters to senior leaders within Theramex. The company claimed it was not aware of any of the matters having been escalated internally prior to them being reported to the regulator. As part of the sanction, Theramex must provide written confirmation that it will cease practices that breach codes, pay a charge and advertise details of the case. Theramex UK said it 'absolutely acknowledges' the recent ruling and 'respects the [regulator's] decision'. 'Of course, we remain fully committed to ensuring our practices align with the highest ethical standards and necessary steps and corrective measures have been taken,' it said.
